Phase I Dose Escalation of the MET Inhibitor XL184 and the BRAF Inhibitor Vemurafenib
Phase of Trial: Phase I
Latest Information Update: 08 Oct 2014
At a glance
- Drugs Cabozantinib (Primary) ; Vemurafenib
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 24 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 01 Jul 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.